Evolus, Inc. (EOLS) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Evolus, Inc. (EOLS) closed at USD 7.22 on 2026-10-14, a change of +2.6 % over the past year, with a market capitalization of USD 500M.

Evolus, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Evolus, Inc. key figures

Previous close

USD 7.22 (2026-10-14)

1-year change

+2.6 %

Market cap

USD 500M

Enterprise value

USD 619.64M

P/E ratio (trailing)

-14.02

P/E ratio (forward)

25.88

EPS (trailing)

-0.54

EPS (forward)

0.29

PEG ratio

n/a

Price to book

-16.18

Revenue growth

21.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.64

Employees

353

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Evolus, Inc.

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Evolus, Inc. and compare it with other stocks.